
Annual report 2025
added 03-04-2026
Sensus Healthcare EBITDA 2011-2026 | SRTS
Earnings before Interest, Taxes, Depreciation, and Amortization (EBITDA), is an often used measure of a company's profitability. Financial analysts use EBITDA for a number of purposes including calculating simple valuations of a firm, estimating cash flows, and assessing debt servicing capability. The uses for EBITDA in financial analysis are numerous, but in practice should be more restrained. While EBITDA has some useful applications, it should be used with caution, as the problems with EBITDA are abundant and can lead to a number of misguided conclusions.[1]
EBITDA is an important indicator for investors and analysts because it allows them to evaluate a company's operating profit without considering the impact of financial expenses, taxes, or non-cash depreciation and amortization. It provides better comparability between companies in different industries or with different tax conditions.
EBITDA is often used to assess a company's ability to generate cash flow and repay debts. It can also serve as a measure of a company's operational efficiency, as it shows how profitable the core business is, regardless of external factors such as interest or taxes.
However, it is important to note that EBITDA is not an official financial statement measure and can be defined and calculated differently by companies. Therefore, investors and analysts should exercise caution when using EBITDA as an evaluation tool and combine it with other financial metrics and information to get a more complete picture of a company's financial condition.
Annual EBITDA Sensus Healthcare
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -9.91 M | 8.29 M | -107 K | 15.1 M | 4.73 M | -7.51 M | -1.42 M | -1.35 M | -3.33 M | -25.5 K | 94.3 K | -3.41 M | 392 K | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 15.1 M | -9.91 M | 123 K |
Quarterly EBITDA Sensus Healthcare
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -2.47 M | -1.84 M | -2.56 M | - | 1.55 M | 2.01 M | 2.96 M | - | -1.84 M | -1.07 M | -2.87 M | - | 2.21 M | 4.74 M | 4.02 M | - | 667 K | 66 K | -907 K | - | -1.8 M | -2.27 M | -3.48 M | - | -390 K | 327 K | -2.06 M | - | 4.07 K | -265 K | -1.01 M | - | -671 K | -574 K | -1.49 M | - | 209 K | -180 K | 94.4 K | - | 173 K | 80.1 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 4.74 M | -3.48 M | -270 K |
References
- Brockman, C. M., & Russell, J. W. (2012). EBITDA: use it... or lose it?. International Journal of Business, Accounting and Finance, 6(2), 84-93.
EBITDA of other stocks in the Medical devices industry
| Issuer | EBITDA | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
FONAR Corporation
FONR
|
9.84 M | $ 18.59 | -0.08 % | $ 122 M | ||
|
GenMark Diagnostics, Inc.
GNMK
|
-3.98 M | - | - | $ 1.77 B | ||
|
Acutus Medical
AFIB
|
-11.5 M | - | -26.83 % | $ 2.62 M | ||
|
Globus Medical
GMED
|
757 M | $ 89.93 | 1.5 % | $ 12.2 B | ||
|
AdaptHealth Corp.
AHCO
|
473 M | $ 11.93 | -1.16 % | $ 1.61 B | ||
|
Allied Healthcare Products
AHPI
|
-815 K | - | 3.58 % | $ 2.21 M | ||
|
ClearPoint Neuro
CLPT
|
-23.4 M | $ 8.97 | -4.37 % | $ 254 M | ||
|
Helius Medical Technologies
HSDT
|
-12.4 M | $ 1.81 | -4.74 % | $ 1.1 M | ||
|
Integra LifeSciences Holdings Corporation
IART
|
70.8 M | $ 9.28 | -0.32 % | $ 715 M | ||
|
Obalon Therapeutics, Inc.
OBLN
|
-9.8 M | - | -5.86 % | $ 30.6 M | ||
|
Bruker Corporation
BRKR
|
437 M | $ 36.52 | -0.6 % | $ 5.44 K | ||
|
IRIDEX Corporation
IRIX
|
-2.05 M | $ 1.03 | 3.75 % | $ 17.4 M | ||
|
Integer Holdings Corporation
ITGR
|
352 M | $ 85.18 | -0.53 % | $ 2.96 B | ||
|
LENSAR
LNSR
|
-21 M | $ 5.6 | -4.92 % | $ 67 M | ||
|
Apollo Endosurgery
APEN
|
-30.2 M | - | - | $ 475 M | ||
|
Medtronic PLC
MDT
|
8.82 B | $ 86.91 | 0.73 % | $ 112 B | ||
|
OrthoPediatrics Corp.
KIDS
|
-18.1 M | $ 15.77 | -1.07 % | $ 370 M | ||
|
Myomo
MYO
|
-13.5 M | $ 0.66 | -5.91 % | $ 27.6 M | ||
|
EDAP TMS S.A.
EDAP
|
-17.9 M | $ 3.42 | -1.16 % | $ 128 M | ||
|
CryoLife, Inc.
CRY
|
23.2 M | - | -4.14 % | $ 702 M | ||
|
Orthofix Medical
OFIX
|
-4.11 M | $ 11.74 | -0.25 % | $ 465 M | ||
|
Avinger
AVGR
|
-16.3 M | - | -20.74 % | $ 369 K | ||
|
Align Technology
ALGN
|
753 M | $ 167.92 | -2.3 % | $ 12.6 B | ||
|
AxoGen
AXGN
|
-1.19 M | $ 30.92 | -5.27 % | $ 1.42 B | ||
|
Axonics Modulation Technologies
AXNX
|
-53.2 M | - | - | $ 3.31 B | ||
|
Insulet Corporation
PODD
|
564 M | $ 202.76 | -0.36 % | $ 14.3 B | ||
|
Aziyo Biologics
AZYO
|
-24.1 M | - | 1.37 % | $ 20.5 M | ||
|
Soliton, Inc.
SOLY
|
-14.1 M | - | -1.42 % | $ 435 M | ||
|
Hancock Jaffe Laboratories, Inc.
HJLI
|
88.4 K | - | -1.98 % | $ 98.3 M | ||
|
Itamar Medical Ltd.
ITMR
|
-8.53 M | - | 0.03 % | $ 1.58 B | ||
|
Misonix, Inc.
MSON
|
-15.9 M | - | - | $ 462 M | ||
|
Neovasc
NVCN
|
-31.1 M | - | - | $ 111 M | ||
|
Sintx Technologies
SINT
|
-10.4 M | $ 2.68 | 5.93 % | $ 7.43 M | ||
|
Smith & Nephew plc
SNN
|
1.16 B | $ 31.78 | -2.6 % | $ 23.8 B | ||
|
Stryker Corporation
SYK
|
6.46 B | $ 332.16 | -0.04 % | $ 127 B | ||
|
Butterfly Network
BFLY
|
-65.5 M | $ 4.0 | -3.27 % | $ 847 M | ||
|
Tactile Systems Technology
TCMD
|
35.9 M | $ 24.1 | -1.91 % | $ 551 M | ||
|
Intersect ENT, Inc.
XENT
|
-64.8 M | - | - | $ 955 M | ||
|
Cytosorbents Corporation
CTSO
|
-13.5 M | $ 0.6 | 1.69 % | $ 37.3 M | ||
|
Tandem Diabetes Care
TNDM
|
26 M | $ 18.34 | -4.36 % | $ 1.25 B | ||
|
BIOLASE
BIOL
|
-15.1 M | - | -13.19 % | $ 166 K | ||
|
Delcath Systems
DCTH
|
898 K | $ 9.68 | -0.17 % | $ 347 M | ||
|
BioSig Technologies
BSGM
|
-67.6 M | - | 37.08 % | $ 85.7 M | ||
|
Boston Scientific Corporation
BSX
|
4.98 B | $ 61.76 | -1.33 % | $ 91.4 B | ||
|
Alphatec Holdings
ATEC
|
-4.64 M | $ 11.07 | 0.87 % | $ 1.66 B | ||
|
Varex Imaging Corporation
VREX
|
-4.6 M | $ 10.53 | -0.28 % | $ 436 M | ||
|
CONMED Corporation
CNMD
|
120 M | $ 34.75 | 1.97 % | $ 1.08 B | ||
|
Edwards Lifesciences Corporation
EW
|
1.42 B | $ 81.0 | -0.23 % | $ 47.4 B |